What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD);…
What is Supernus Pharmaceuticals, Inc.'s P/E and P/B ratio?
Supernus Pharmaceuticals, Inc. has a P/E ratio of -21.2 and a P/B ratio of 2.30.
What is Supernus Pharmaceuticals, Inc.'s debt-to-equity ratio?
Supernus Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.04.
How much does Supernus Pharmaceuticals, Inc. owe compared with what it owns?
Supernus Pharmaceuticals, Inc. owes $0.28 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Supernus Pharmaceuticals, Inc.'s Positivity rank?
Supernus Pharmaceuticals, Inc. is ranked #4,384 of 6,775 companies globally and #2,167 of 4,000 in United States on PositoAI, with a Positivity Score of 19,554.
Does Supernus Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Supernus Pharmaceuticals, Inc..
Where can I read the latest news about Supernus Pharmaceuticals, Inc.?
Recent headlines about Supernus Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Supernus Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Supernus Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.